Drexler H G, Meyer C, Gaidano G, Carbone A
DSMZ-German Collection of Microorganisms & Cell Cultures, Department of Human and Animal Cell Cultures, Braunschweig.
Leukemia. 1999 Apr;13(4):634-40. doi: 10.1038/sj.leu.2401371.
Primary effusion lymphoma (PEL) is a new lymphoma entity occurring predominantly, but not exclusively in HIV+ patients with acquired immunodeficiency syndrome (AIDS). PEL grows exclusively in body cavities as serous lymphomatous effusion without evidence of mass disease or dissemination. The cells are infected with the newly discovered human herpesvirus-8 (HHV-8), often accompanied by co-infection with Epstein-Barr virus (EBV). Several lymphoma cell lines have been established from patients with AIDS- and non-AIDS-associated PEL. Given their phenotypical relationship to plasma cells, several cytokines may be important for growth and survival of PEL cells. We investigated the spectrum of cytokines produced by nine HHV-8+ PEL cell lines, in comparison with five Burkitt lymphoma, seven other B non-Hodgkin's lymphoma (B-NHL) and seven multiple myeloma-derived cell lines. In addition, we tested the response of the PEL cells to selected cytokines and the effects of neutralizing anti-cytokine and anti-cytokine receptor antibodies. Using specific ELISAs, PEL cell lines were found to produce large amounts of interleukin-6 (IL-6; 10-5000 pg/ml), IL-6 soluble receptor (IL-6sR; 30-600 pg/ml), IL-10 (600-80,000 pg/ml) and oncostatin M (OSM; 50-80 pg/ml) which in most cases were significantly higher than the levels produced by the Burkitt, B-NHL or myeloma cell lines; on the contrary, PEL cell lines did not elaborate significant levels of macrophage inhibitory protein (MIP-1alpha) and leukemia inhibitory factor (LIF). However, the levels of MIP-1alpha were increased 10- to 100-fold by treatment with phorbol ester TPA. PEL cell lines did not respond proliferatively to IL-6, IL-10, IL-11, LIF, MIP-1alpha, or OSM. Incubation with IL-6sR and IL-6 inhibited cell growth. Anti-IL6 neutralizing antibodies had no effect on PEL cell line proliferation; conversely, whereas anti-IL6R alone inhibited only weakly, anti-gp130 and anti-gp130 plus anti-IL6R showed strong inhibitory effects (>20% inhibition in 5/9 lines and >60% inhibition in 3/9 lines). In summary, PEL cell lines produce high amounts of cytokines (IL-6, IL-10, OSM); proliferation could be inhibited by blocking the receptors of the IL-6 signaling pathway.
原发性渗出性淋巴瘤(PEL)是一种新的淋巴瘤实体,主要但并非仅发生于患有获得性免疫缺陷综合征(AIDS)的HIV阳性患者。PEL仅在体腔内以浆液性淋巴瘤性渗出液的形式生长,无肿块性疾病或播散的证据。细胞感染了新发现的人类疱疹病毒8型(HHV-8),常伴有EB病毒(EBV)的共同感染。已从与AIDS相关和非AIDS相关的PEL患者中建立了几种淋巴瘤细胞系。鉴于它们与浆细胞的表型关系,几种细胞因子可能对PEL细胞的生长和存活很重要。我们研究了9种HHV-8阳性PEL细胞系产生的细胞因子谱,并与5种伯基特淋巴瘤、7种其他B细胞非霍奇金淋巴瘤(B-NHL)和7种多发性骨髓瘤衍生细胞系进行了比较。此外,我们测试了PEL细胞对选定细胞因子的反应以及中和抗细胞因子和抗细胞因子受体抗体的作用。使用特异性酶联免疫吸附测定法(ELISA),发现PEL细胞系产生大量白细胞介素-6(IL-6;10 - 5000 pg/ml)、IL-6可溶性受体(IL-6sR;30 - 600 pg/ml)、IL-10(600 - 80,000 pg/ml)和制瘤素M(OSM;50 - 80 pg/ml),在大多数情况下,这些水平显著高于伯基特淋巴瘤、B-NHL或骨髓瘤细胞系产生的水平;相反,PEL细胞系未产生显著水平的巨噬细胞抑制蛋白(MIP-1α)和白血病抑制因子(LIF)。然而,用佛波酯TPA处理后,MIP-1α的水平增加了10至100倍。PEL细胞系对IL-6、IL-10、IL-11、LIF、MIP-1α或OSM无增殖反应。与IL-6sR和IL-6共同孵育可抑制细胞生长。抗IL-6中和抗体对PEL细胞系增殖无影响;相反,单独的抗IL-6R仅产生微弱抑制作用,而抗gp130以及抗gp130加抗IL-6R则显示出强烈的抑制作用(5/9的细胞系抑制率>20%,3/9的细胞系抑制率>60%)。总之,PEL细胞系产生大量细胞因子(IL-6、IL-10、OSM);阻断IL-6信号通路的受体可抑制其增殖。